What Are Early Phase Studies? A Guide to Clinical Research and New Medicines
Early Phase Studies are an important first step in understanding whether a new medicine or investigational treatment can safely move forward in clinical development. Before a promising treatment can potentially become available to patients, researchers need reliable evidence about how it behaves in the human body, how people respond to it, and what doses may be appropriate for further research.
For people who are unfamiliar with clinical research, terms such as Phase I, First-in-Human, dose escalation, pharmacokinetics and pharmacodynamics can seem complicated. Understanding these concepts makes it easier to see how new medicines are carefully evaluated before progressing into larger clinical trials.
What Are Early Phase Studies?
Early phase studies are clinical research studies conducted at the beginning of human development for a new medicine, treatment, device or other investigational product.
They are designed to answer important early questions, such as:
Is the investigational treatment safe and tolerable?
How does the body absorb, distribute, metabolise and eliminate it?
What happens after different doses are administered?
How does the treatment affect the body?
What dose or dosing schedule should be investigated in later studies?
Are there any important safety signals researchers need to monitor?
These studies provide essential information that helps researchers and sponsors make informed decisions about the next stage of clinical development.
Early-phase research can involve healthy volunteers, patients, or both, depending on the investigational product, study design and therapeutic area.
Why Are Early Phase Studies Important?
Developing a new medicine is a complex process. Laboratory research and preclinical studies can provide valuable information, but researchers ultimately need to understand how an investigational product behaves in humans.
Early clinical research helps bridge that gap.
A well-designed early-phase study can generate critical data about safety, tolerability, pharmacokinetics and pharmacodynamics. This information can help sponsors determine whether and how a medicine should progress into later-stage development.
From Research Concept to Human Study
A simplified development pathway may look like this:
Discovery and laboratory research – Scientists identify and investigate a potential treatment.
Preclinical research – Researchers evaluate the investigational product before human testing.
First-in-Human research – Carefully controlled studies begin in people when appropriate.
Early clinical development – Researchers investigate safety, tolerability, dose and drug behaviour.
Later clinical trials – Larger studies examine efficacy and continue evaluating safety.
Regulatory review – Evidence from clinical development contributes to regulatory submissions and decisions.
The process is not always completely linear, and the appropriate pathway depends on the investigational product and its development strategy.
What Happens During an Early Phase Study?
The exact procedures vary according to the protocol, but participants may undergo several assessments before, during and after receiving the investigational treatment.
These may include:
Medical history and physical examinations
Vital-sign monitoring
Blood or urine testing
Electrocardiograms (ECGs)
Pharmacokinetic sampling
Pharmacodynamic assessments
Adverse-event monitoring
Clinical observations
Follow-up assessments
The study team follows a predefined protocol and monitors participants throughout the study.
Safety is a central consideration. Depending on the study design, participants may remain at the research facility for a specified period so that trained clinical staff can monitor them closely.
Understanding Phase I Clinical Research
Phase I studies are commonly associated with the early stages of human clinical development.
A Phase I study may investigate a new investigational medicine in healthy volunteers, although some medicines—particularly treatments for certain serious diseases—may be studied directly in patients.
One important objective is to understand how the investigational product behaves in the human body.
What Are SAD and MAD Studies?
Two common early-phase study designs are Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.
SAD studies generally evaluate increasing single doses in separate participant groups. Researchers can assess safety, tolerability and pharmacokinetic characteristics at different dose levels.
MAD studies evaluate repeated doses over a defined period. They can help researchers understand what happens when an investigational product is administered multiple times.
The exact dose levels, schedules and participant numbers are determined by the study protocol.
The Role of Pharmacokinetics and Pharmacodynamics
Two important concepts in early clinical development are pharmacokinetics (PK) and pharmacodynamics (PD).
Pharmacokinetics: What the Body Does to the Medicine
Pharmacokinetics examines how the body handles an investigational product.
Researchers may look at:
Absorption
Distribution
Metabolism
Excretion
Concentration of the medicine in the blood over time
PK data can help researchers understand how long a medicine remains in the body and how exposure changes at different doses.
Pharmacodynamics: What the Medicine Does to the Body
Pharmacodynamics examines the effects of the investigational product on the body.
Depending on the treatment, researchers may assess biological markers, physiological responses or other measurable effects.
Together, PK and PD information can help inform future dosing strategies and clinical development decisions.
Other Types of Early Phase Research
Early-phase clinical development can involve more than basic dose-escalation studies.
Depending on the development program, studies may investigate:
Food Effect Studies
These studies examine whether taking an investigational medicine with food changes its exposure or other pharmacokinetic characteristics.
Drug-Drug Interaction Studies
Drug-drug interaction studies investigate whether one medicine changes the effects or exposure of another medicine when administered together.
Bioequivalence Studies
These studies can compare the pharmacokinetic characteristics of different formulations or products when appropriate.
Biosimilar Studies
Early clinical studies may contribute to the development and characterisation of biosimilar products.
First-in-Patient Studies
Some investigational treatments are more appropriately evaluated in people who have the condition the treatment is intended to address.
This is particularly relevant in areas such as oncology and other specialised therapeutic fields.
Scientia Clinical Research has experience across a broad range of early-phase study designs, including SAD, MAD, food-effect, DDI, pharmacokinetic, biosimilar, pharmacodynamic and efficacy studies. Its experience also includes First-in-Human and targeted first-in-patient research.
Who Can Participate in Early Phase Studies?
Eligibility depends entirely on the individual study protocol.
Some studies are designed for healthy volunteers, while others require participants with a particular medical condition.
Before participation, potential participants generally undergo a screening process to determine whether they meet the study's eligibility criteria.
Criteria may include factors such as:
Age
Medical history
Current medications
General health
Previous clinical trial participation
Laboratory results
Specific disease characteristics, where applicable
Meeting the initial criteria does not automatically guarantee participation. The research team makes eligibility decisions according to the approved study protocol.
For patient studies, participants should also discuss clinical trial participation with their treating healthcare professional where appropriate. Scientia works with patients, healthcare professionals and referral networks to support participation in relevant clinical research.
Why Is Clinical Oversight So Important?
Early-phase studies can involve investigational treatments that are still being evaluated. This makes appropriate medical oversight, participant monitoring and study procedures particularly important.
A dedicated research environment can bring together:
Experienced clinical research professionals
Medical oversight
Nursing support
Participant monitoring
Laboratory capabilities
Investigational product management
Clinical research infrastructure
Established emergency support
Scientia's Sydney facility provides 24/7 participant monitoring and has a dedicated service agreement with Prince of Wales Hospital, supporting access to emergency care when required. The organisation also reports experience across more than 300 completed studies since opening.
What Makes a High-Quality Early Phase Study?
The quality of an early-phase study depends on much more than simply administering an investigational treatment.
Important factors include:
1. A Well-Designed Protocol
The study should have clearly defined objectives, endpoints, eligibility criteria, dosing procedures and safety-monitoring requirements.
2. Experienced Clinical Teams
Early-phase research requires teams who understand the specific demands of Phase I and First-in-Human studies.
3. Strong Participant Recruitment
Recruitment needs to match the protocol requirements while maintaining appropriate screening and participant safety.
4. Reliable Data Collection
Accurate collection and management of clinical, laboratory and pharmacokinetic data are essential for meaningful study results.
5. Appropriate Facilities
The research facility should have the infrastructure and systems required for the specific study design.
6. Effective Communication
Clear communication between sponsors, investigators, research staff, participants and other stakeholders can help minimise delays and maintain study quality.
Why Consider Australia for Early Phase Clinical Research?
Australia has become an attractive location for early clinical development because of its established research infrastructure, experienced healthcare professionals and regulatory environment.
Scientia highlights several advantages for sponsors, including Australia's clinical research capabilities, diverse population, research infrastructure and potential to accelerate early development timelines.
For sponsors planning an international clinical development program, the Australian setting can therefore form an important part of an early-phase strategy.
How Scientia Clinical Research Supports Early Phase Development
Scientia Clinical Research is a dedicated Phase I clinical trial unit in Sydney with a strong focus on First-in-Human and early-phase research.
The organisation's experience includes both healthy-volunteer and patient studies, with capabilities spanning therapeutic areas such as oncology, haematology, neurology, cardiology, endocrinology, immunology and vaccines.
Its experience and infrastructure are designed to support sponsors through key stages of early clinical development, including study planning, start-up, clinical conduct, participant recruitment and study management.
Scientia also operates as a not-for-profit organisation and focuses on advancing clinical research while maintaining strong standards of quality, safety, collaboration and participant care.
Key Takeaways for Anyone Exploring Early Clinical Research
If you are trying to understand early-phase clinical development, remember these key points:
Early-phase research is an important stage of human clinical development.
Phase I studies often focus on safety, tolerability, dose and drug behaviour.
First-in-Human studies require careful planning and close medical monitoring.
PK and PD assessments provide important information about an investigational treatment.
Studies may involve healthy volunteers or patients depending on the investigational product and protocol.
SAD, MAD, food-effect, DDI and other study designs can answer different development questions.
Experienced clinical research teams and appropriate infrastructure are essential for conducting high-quality early-phase studies.
Conclusion
Early clinical research provides an important bridge between scientific discovery and the development of potential new medicines. By carefully evaluating safety, tolerability, dosing, pharmacokinetics and pharmacodynamics, researchers can generate the evidence needed to make informed decisions about future clinical development.
For sponsors, selecting an experienced early-phase research partner can be an important part of delivering a study efficiently and to a high standard. For participants, taking part in appropriate clinical research can contribute to the development of future treatments.
With extensive Phase I experience, First-in-Human capabilities, patient-study expertise and purpose-built clinical research infrastructure, Scientia Clinical Research supports the early development of investigational medicines and helps turn promising scientific ideas into carefully evaluated clinical research.
Frequently Asked Questions About Early Phase Studies
1. What are Early Phase Studies?
Early Phase Studies are clinical research studies conducted during the initial stages of human development of an investigational medicine, treatment or other product. They commonly investigate safety, tolerability, dose and how the treatment behaves in the body.
2. Are Early Phase Studies the same as Phase I trials?
They can overlap significantly. Phase I is commonly considered part of early clinical development, although terminology can vary depending on the study and development program.
3. Who participates in early-phase clinical trials?
Depending on the study, participants may be healthy volunteers or people with a specific medical condition. Eligibility is determined according to the individual study protocol.
4. What is a First-in-Human study?
A First-in-Human study is a clinical study in which an investigational treatment is administered to humans for the first time. These studies require careful planning, appropriate oversight and close participant monitoring.
5. Why are early-phase studies important for new medicines?
They generate important human data about safety, tolerability, pharmacokinetics, pharmacodynamics and dosing. This evidence can help researchers and sponsors decide how a treatment should progress through clinical development.
Comments